Poly-beta-1,6-N-acetylglucosamine (PNAG)

Poly-beta-1,6-N-acetylglucosamine (PNAG) is a conserved surface polysaccharide and a primary component of the extracellular biofilm matrix produced by a wide range of Gram-positive and Gram-negative bacterial pathogens, including Staphylococcus aureus, Escherichia coli, and Klebsiella pneumoniae (PMID: 15231743, 2823386). It plays a critical role in bacterial virulence by mediating cell-to-cell adhesion and providing a physical barrier that protects the microbial community from host immune defenses and antibiotic penetration (PMID: 11544343). As a therapeutic target, PNAG is highly attractive due to its broad expression across diverse species, making it a candidate for pan-bacterial vaccines and immunotherapies. Current drug development efforts focus on monoclonal antibodies, such as F598, which promote opsonophagocytic killing, and conjugate vaccines like AV0328 designed to elicit long-lasting protective immunity (PMID: 24595238). Additionally, enzymes like Dispersin B are being explored to degrade PNAG, thereby disrupting biofilms and increasing bacterial susceptibility to conventional antibiotics. This target represents a significant opportunity for treating chronic and device-related infections where biofilm formation is a major complication.

Other names

PNAGPoly-N-acetylglucosaminePolysaccharide Intercellular AdhesinPIAdPNAGDeacetylated poly-N-acetylglucosamine

Monoclonal antibodies (e.g., F598) bind to PNAG on the bacterial surface to mediate opsonophagocytic killing by host immune cells. Vaccines (e.g., AV0328) induce the production of protective antibodies against PNAG. Enzymatic agents like Dispersin B directly hydrolyze the beta-1,6-glycosidic bonds within the PNAG polymer, leading to the physical dispersal of biofilms.